One of the strategies to promote an antitumor response is the genetic modification of tumor cells to induce expression of costimulatory molecules. We have tested the capacity of a soluble form of CD70 molecule (sCD70). After construction of a vector carrying the sCD70, we obtained stable sCD70-secreting TS/A tumor cells and allogenic MC57 fibroblasts. In all, 45% of wild-type (wt) tumors were rejected in immunocompetent mice when transfected sCD70-secreting cells were injected three times in the periphery of the wt tumors. Furthermore, the sCD70-secreting TS/A cells induced a protective memory against wt TS/A tumor growth: 70% of the wt tumors used for the challenge were rejected by mice, which had rejected tumors 45 days before in the presence of sCD70-secreting TS/A cells. It was also shown that in vitro mock TS/A tumor cell proliferation was inhibited by splenocytes harvested from mice injected with TS/A cells expressing CD70. Growth kinetics of wt TS/A tumors in immunocompetent versus nude mice suggested that T lymphocytes were implicated in the antitumor response, which was confirmed by membrane expression of specific markers. The data suggest that injection of genetically transfected cells secreting sCD70 in the periphery of wt TS/A tumors induces T-cell-mediated inhibition of tumor growth and builds up a protective antitumor memory.
A ccording to the two-signal model, optimal T-cell activation requires specific antigen recognition by lymphocytes as well as an additional signal. 1, 2 The first signal is induced by the engagement of the T-cell receptor (TCR) with the couple peptide-antigen/major-histocompatibility complex (MHC). The second signal is induced through the costimulatory molecules and, in the absence of this costimulatory signal, T lymphocytes are anergized. 3 Tumor cells are antigenic and can be recognized by tumor-specific T lymphocytes. The downregulation or absence of MHC molecule expression on the tumor cells is a very frequent mechanism by which tumors escape the host's immune system. 4, 5 Furthermore, tumor cells seldom express costimulatory molecules. So, the tumorassociated antigens (TAAs) specific T clones are anergized. Therefore, one promising strategy to raise a protective antitumor response is the injection of tumor cells transfected with cDNA-encoding costimulatory molecules. Experiments carried out in many mice models, with costimulatory molecules, such as CD28, CD40 or CD27 and their respective ligands CD80, CD154 and CD70, have resulted in tumor rejection and generation of antitumor immunity against parental tumor cells. [6] [7] [8] CD70 is a type II transmembrane glycoprotein, a member of the tumor necrosis factor (TNF) superfamily, which includes CD154 and CD95. 9 Both human and murine T lymphocytes express CD70 and the CD27 ligand. 10, 11 CD70 expression is induced on activated T and B lymphocytes and NK cells after antigenic stimulation, whereas CD27 is constitutively expressed on resting T, B and NK cells.
12 CD27/CD70 interactions are involved in the induction of T-cell proliferation and in antigen-specific cytotoxic T lymphocyte activity. Upon presentation of its specific antigen by antigen presenting cells (APC) in association with a costimulatory signal via CD28/CD80, the naive T lymphocytes become activated, following which CD27 expression is upregulated and high CD70 expression is induced. Interactions between CD27 and CD70 on T lymphocytes induce clonal expansion of these cells. 13 This costimulation provokes production of various cytokines such as interleukin2 (IL-2) and interferon-g (IFN-g). 8 Recently, it was shown that CD27/CD70 interactions also play a role as a costimulatory factor in Tcell cytotoxicity involving the perforin/granzyme B pathway. 14 In several murine tumor models, it was shown that genetically transfected tumor cells expressing CD70 were able to enhance a specific T-cell response and in particular that of CD8 þ T lymphocytes mediating cytotoxic antitumor immunity. 15 Furthermore, it was also shown that CD70 expression can favor the beginning of a long memory T-cell response. Lastly, it was recently reported that CD70/CD27 interactions can mediate primary tumor rejection by NK cells and induce a tumor-specific T-cell memory via an NK cell primary response. 16 Therefore, the CD70 costimulatory molecule appears to be promising in enhancing immune antitumor strategies.
TNF receptor family members, such as CD27, CD40 and CD95, exist in transmembrane and soluble forms and the ligands of CD40 (CD154) and CD95 are also present in both forms. 9 Indeed, soluble CD27 (sCD27) is released in the supernatants of activated T lymphocytes, and is also detected in the serum and urine of healthy individuals and patients. 17, 18 Furthermore, the CD154 molecule and the costimulatory CD80 molecule, belonging to the immunoglobulin family, have been detected in active soluble forms (sCD154 and sCD80). 19, 20 Indeed, the transmembrane forms and the soluble forms of CD154 and CD80 have been efficient in antitumor protocols, [21] [22] [23] which is encouraging for subsequent human clinical therapies because of their simplified use. As yet, native sCD70 molecules have never been detected, although the properties of their transmembrane form suggest that sCD70 would be an interesting tool for the induction of a protective antitumor immune response.
Murine and human CD70 molecules have an overall homology of 62% and the amino acids involved in the ligand receptor interaction showed 68% homology. It must be emphasized that species specificity is not observed at a functional level. 11 Indeed, human CD70 has been used in murine models and murine CD70 in a human cell line, and both molecules were active.
11,15 Therefore, we constructed a viral-derived vector containing cDNA encoding the soluble human form of the CD70 molecule, by the deletion of intracellular and transmembrane CD70 domains, and the fusion between the obtained cDNA sequence encoding the extracellular CD70 domain and a signal peptide sequence. Using this construct, we permanently transfected the MHC class I-positive (H-2   d   ) murine  mammary adenocarcinoma TS/A cells and an allogenic  murine fibroblast cell line MC57 (H-2   b ). This allowed the effect of the sCD70 molecule on tumor growth to be studied in vivo. The results show that sCD70 secretion by tumor cells or by allogenic fibroblasts in the periphery of tumors induces an antitumor-protective immune response and a long-lasting memory response against the wild-type (wt) tumor cells. Furthermore, in vivo and in vitro experiments suggest that it is the T lymphocytes that are mainly involved in this inhibition of tumor growth.
Materials and methods

Cell lines
TS/A is a tumor cell line derived from a spontaneous mammary adenocarcinoma of BALB/c mice (H-2 d strain) kindly provided by P Lollini (Bologna, Italy). MC57 fibroblasts (H-2 b ) allogenic to BALB/c mice (H-2 d ) were kindly provided by JE Gairin (Toulouse, France). These tumor cells and fibroblasts were maintained in vitro by serial passages in RPMI 1640 medium (BioMe´dia, Boussens, France) supplemented with 10% heat-inactivated fetal calf serum (FCS) (BioMe´dia, Boussens, France).
Mice
Female BALB/c or BALB/c nu/nu mice (6 weeks old) were purchased from, respectively, CERJ JANVIER (Le Genest St-Isle, France) and Charles River Laboratoire (L'Arbresle, France) and were maintained in a pathogenfree animal facility prior to subcutaneous (s.c.) inoculation of tumors.
Retroviral construct generation and transfectant cells
The construction and characterization of the DFG human CD70 (DFG CD70) retroviral vector have been described previously. 24 This MFG-based retroviral vector expresses the CD70 molecule along with an encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES) neo R sequence-selectable marker, encoding resistance to G418.
The control vector (mock) consists of the MFG retroviral vector with IRES neo R sequence. 24 We deleted the 38 NH 2 -terminal a.a. (intracellular and transmembrane domains) and introduced a new translation initiation codon upstream from the CD5 signal peptide cDNA sequence. 25 This sequence was fused with the cDNA sequence encoding the extracellular domain of hCD70 to favor secretion. The cDNA encoding the soluble form of hCD70 (sCD70) molecule was generated by PCR cloning from full-length hCD70 cDNA.
To introduce this sequence, the following primers were used: sCD70 sense primer: 5 0 -ATGCCCATGGGCTC TCTGCAGCCGCTGGCCACCTTGTACCTGCTGGGG ATGCTGGTCGCTTCCTGCCTCGGACAGCGTTCGC ACAGGCTCAGCAG-3 0 ; sCD70 antisense primer: 5 0 -CGGGATCCCTAATCAGCAGCAGTG-3 0 . The forward primer contains a NcoI site and the reverse primer contains a BamHI site. This PCR product was cloned into the MFGbased retroviral vector containing an IRES neo R sequence (named DFG) to obtain the expression vector DFG sCD70. This construction was DNA sequenced to confirm sequence fidelity.
Tumor TS/A CD70 cells, and TS/A sCD70 cells, fibroblasts MC57 CD70 and MC57 sCD70 were obtained, respectively, by transfection of TS/A cell line and MC57 fibroblasts with the DFG CD70 Neo and DFG sCD70 Neo, using a transfection kit, LIPOFEC-TAMINE PLUSt, as described by the supplier (Gibco-BRL, Cergy Pontoise, France). The control cells TS/A mock and MC57 mock were obtained by transfection with the MFG mock retroviral vector. Stably transfected cells were selected using G418 (1 mg/mL). Four clones, with the highest expression of CD70 or secretion of sCD70 molecules, were pooled and used for all experiments. 
Flow cytometry analysis
Western-blot analysis
Proteins present in the supernatant culture medium of transfected cells were precipitated in pure acetone overnight at 41C. The acetone was removed and the proteins were resuspended in 100 mL lysis buffer (Ref. (1) either two simultaneous and identical injections in both flanks of mice with the mixture of cells on day 0, or (2) these injections were followed by three more injections containing only the 5 Â 10 4 transfected and g-ray-irradiated TS/A tumor cells or MC57 fibroblasts on days 4, 8 and 12 into both flanks. All these injections were performed simultaneously (one in each flank) in 100 ml of PBS. Tumor growth was determined by measuring the diameter of the tumors in two dimensions. Mice that did not develop tumors after 45 days received a subsequent challenge of 5 Â 10 4 live wt TS/A in both flanks.
Assay to detect splenocyte-induced inhibition of in vitro tumor cell proliferation Spleens were harvested from three groups of mice that were injected with mock, CD70-or sCD70-transfected irradiated TS/A cells. The mock group was composed of naive mice, whereas the CD70 and sCD70 groups used the appropriate tumor-free mice that had been challenged 45 days before. Spleens were minced. Single-cell suspensions were prepared and red blood cells were removed with erythrocyte lysis buffer (0.01 M Tris HCl, 0.83% NH 4 Cl, pH 7.4). The splenocytes were stimulated in vitro by incubating 2 Â 10 6 splenocytes for 7 days with 2 Â 10 4 irradiated (100 Gy) tumor cells, either mock-TS/A, CD70 TS/A or sCD70 TS/A, in 24-well plates. These stimulations were performed at 371C in a 5% CO 2 humidified atmosphere in RPMI-10% FCS in the presence of 50 IU/ mL hIL-2r (Proleukin s , Chiron, Suresnes, France). The stimulated splenocytes were then harvested and cocultured with live tumor cells at a ratio of 1000/1 (10 6 splenocytes with 10 3 tumor cells) in 2 mL of RPMI-10% FCS and 50 IU/mL hIL-2r for 4 days. Nonadherent cells were washed out with cold PBS and the adherent live tumor cells were then trypsinized, washed once, and resuspended in 1 mL of RPMI-10% FCS. A volume of 100 mL of this tumor cell suspension was put in culture in triplicate in 96-well round-bottomed plates. After 78 hours of culture and for the last 18 hours, the tumor cells were pulsed with 0.5 mCi/well 3 H-thymidine (Amersham Life Science, Buckinghamshire, UK). The cells were assayed for thymidine incorporation using a b-counter. The data represent means of three triplicate cultures.
Results
Presence of CD70 molecules on membrane or in culture supernatant of transfected cells
To test the efficiency of CD70 in antitumor immunity, we constructed two MFG-based vectors expressing fulllength or extracellular domain CD70 coupled with a neo R selectable marker as described in Materials and methods. Full-length CD70 vector was constructed to obtain membrane expression of the molecule whereas extracellular domain CD70 vector gave a soluble form of the molecule. These vectors were used to compare the biological effects of membrane-expressed and soluble forms of the CD70 molecule. The MFG mock (IRES neo R ) vector was the negative control in our experiments (Fig 1a) .
TS/A tumor cells and MC57 fibroblasts were stably transfected (as described in Materials and methods) with MFG mock, DFG CD70 or DFG sCD70 vectors. We first tested the membrane expression of CD70 on transfected TS/A tumor cells and on transfected MC57 fibroblasts by cytofluorometry using a PE-conjugated antibody specific for human CD70 (Fig 1b) . Increased membrane expression of CD70 was observed with DFG CD70-transfected cells (Fig 1b) . The results also show that CD70 expression was not observed in DFG sCD70-transfected cells, which suggests that CD70 molecules were secreted by these transfected cells. The production of CD70 by transfected cells was monitored by Western blot. This confirmed the presence of secreted CD70 in the supernatant of DFG sCD70-transfected cells. Furthermore, CD70 molecules were detected in the cellular protein extracts from cells transfected with DFG CD70 (Fig 1c) . All the following experiments described in this work were carried out with the same pool of clones. To obtain these pools, we selected the four clones with the highest CD70 expression for each condition: DFG CD70 or DFG sCD70 transfected in TS/A or in MC57 cells. For negative controls, two pools of four TS/A or MC57 clones transfected with MFG mock were used. Furthermore, before each in vivo or in vitro experiment, three controls were carried out. Firstly, sCD70 secretion by the sCD70- Antitumor immunity induced by soluble CD70 C Cormary et al transfected pool of cells was checked by Western blot; secondly, membrane CD70 expression by the CD70 cell pool was checked by cytofluorometry; and, finally, absence of membrane or soluble CD70 molecules by the pool of mock-transfected cells was checked using both techniques. As illustrated in Figure 1b and c, the DFG CD70 and DFG sCD70 vectors induced significant CD70 expression on the membrane or in the supernatant of transfected cells, respectively.
Inhibition of wt tumor growth induced by injection of sCD70-secreting TS/A tumor cells
The ability of sCD70-secreting tumor cells to elicit a protective immunity against parental tumor cell development in vivo was investigated. Immunocompetent BALB/c mice were injected simultaneously with a mixture of 5 Â 10 4 wt live TS/A tumor cells plus 5 Â 10 4 transfected and irradiated TS/A tumor cells as described in Materials and methods. Only the wt TS/A tumor cells can grow, because the irradiation (100 Gy) of transfected TS/A cells stops the growth but allows sCD70 secretion for 4 days. The capacity of sCD70-transfected cells to secrete sCD70 molecule after 100 Gy irradiation was checked in vitro (data not shown). Figure 2a illustrates the effects of timelimited (a single injection on day 0) sCD70 secretion in TS/A wt tumor development observed in immunocompetent BALB/c mice. In all, 20% of the tumors were rejected when they were mixed with irradiated sCD70 TS/A cells, whereas when they were mixed with irradiated mock or CD70 TS/A cells, none of the injected wt tumors were rejected. To evaluate the effect of prolonged sCD70 secretion on tumor growth, the irradiated and transfected tumor cells were reinjected three times on days 4, 8 and 12 after the first injection. The results show that this longterm sCD70 secretion in the periphery of wt tumors improves the rejection of tumors. Indeed, 45.2% of wt tumors did not develop in mice injected four times with sCD70-irradiated tumor cells (Fig 2b) . These percentages remained unchanged for 2 months. However, it should be noted that four reinjections with MFG mock and DFG CD70-transfected irradiated cells also weakly increased the percentage of nondeveloped wt tumors. These results suggest that TAAs-peptides/MHC-I complexes present on wt TS/A tumor cells are able to induce an antitumor immune response when several in vivo stimulations are performed. However, as shown in Table 1 , wt tumor growth also weakly decreased without reinjection of sCD70-secreting TS/A transfected cells in comparison with the mock group (as shown by Student's t-test, P ¼ .048). In addition, the tumor growth decrease was amplified by three reinjections of sCD70-secreting TS/A transfected cells, which induced a statistically significant reduction of coinjected wt tumor growth (Po.0001).
Involvement of T lymphocytes in tumor rejection induced by sCD70-secreting TS/A tumor cells
To evaluate the involvement of T lymphocytes in these in vivo antitumor responses, the same populations of cells were injected in parallel into athymic T-cell-deficient BALB/c nu/nu mice and into immunocompetent BALB/c mice. As for previous experiments, mice were first injected with a mixture of 5 Â 10 4 live wt TS/A tumor cells and 5 Â 10 4 irradiated mock or sCD70-transfected TS/A tumor cells and restimulated three times by the irradiated transfected tumor cells.
Growth kinetics of wt tumors in BALB/c mice differ when wt tumor cells were coinjected with mock or with sCD70-transfected tumor cells. However, in nude mice, wt tumors grew with similar kinetics regardless of the type of transfected cells used for reinjection (Fig 3) . Therefore, these results showed that T-lymphocyte responses were involved in the antitumor response induced in immunocompetent BALB/c mice by sCD70-secreting TS/A cells. 
Induction of splenic T lymphocyte activation by injection of sCD70-secreting TS/A tumor cells
To specify whether T lymphocytes or NK cells were involved in tumor cell rejection by BALB/c mice injected with sCD70-transfected cells, the expression of CD27 (the receptor of CD70) was analyzed. Three spleen lymphocyte subpopulations (CD3 þ , CD8 þ and CD16 þ ) from mice injected three times with transfected and irradiated TS/A cells (Fig 2b) were analyzed by flow cytometry on different days. On day 9, an increase of CD3 þ /CD27 þ cells is observed in both groups of mice injected with CD70 expressing TS/A cells, compared to the group of mice injected with mock TS/A cells (Fig 4) . This overexpression of CD3 þ /CD27 þ cells is observed from day 2 onwards after tumor injection. Interestingly, in the group of mice injected with sCD70-secreting TS/A cells, the subpopulation of CD8 þ /CD27 þ cells increased, whereas no difference was observed in the percentage of CD16 þ /CD27 þ cells between the three groups of mice (Fig 4) . These results suggest that in our models CD8 þ T lymphocytes are involved in the antitumor response, since we did not observed an NK cells activation. Moreover, an increased expression of CD25 was observed in splenocytes harvested from mice injected with sCD70-secreting TS/A autologous tumor cells (CD25 mean fluorescence: 23.6) compared to CD25 expression on splenocytes from mice injected with mock-transfected TS/A cells (CD25 mean fluorescence: 14) (data not shown). This increased expression is similar to that observed in the mice injected with an allogenic tumor cell line (B16F10) (CD25 mean fluorescence: 20.2). This increased expression of CD25 could be linked to the presence of activated T lymphocytes.
Effect of sCD70 secretion by MC57-irradiated fibroblasts on wt TS/A tumor growth in vivo
The ability of sCD70-secreting allogenic fibroblasts (MC57) in the periphery of tumors to induce tumor rejection was evaluated in immunocompetent BALB/c mice. A mixture of 5 Â 10 4 live wt TS/A tumor cells (H-2 d ) plus 5 Â 10 4 transfected and irradiated allogenic (H-2 b ) MC57 fibroblasts was injected into both flanks of BALB/ c mice. The fibroblast irradiation dose (75 Gy) allows sCD70 secretion for 4 days, but stops fibroblast proliferation as checked in vitro (data not shown). Injections of allogenic sCD70-secreting fibroblasts induced anti-tumor responses that were similar to those obtained with injections of sCD70-secreting TS/A tumor cells. Figure 5a shows wt tumor development in mice injected only once with wt TS/A and irradiated transfected fibroblasts. Figure 5b represents the results for mice reinjected three times with allogenic irradiated transfected MC57 fibroblasts. Interestingly, 20% of wt tumors were rejected in mice where a short secretion of sCD70 by allogenic fibroblasts was obtained by a single injection, whereas with a long-term secretion of sCD70 by reinjections of allogenic transfected fibroblasts, 48.1% of wt tumors were rejected. The curve of the percentage of nondeveloped tumors with three reinjections of sCD70-secreting MC57 fell to a constant value of 43.3% (on day Immunocompetent BALB/c mice were injected with mixtures of 5 Â 10 4 live wt TS/A tumor cells and 5 Â 10 4 irradiated pools of transfected TS/A or MC57 cells containing either mock, CD70 or sCD70 constructs. The mean tumor size (mm 2 ) of the wt tumors was measured on day 28 postinjection. Two protocols were compared: one consisting of a single injection (0 Rj) on day 0, and the second consisting of the first injection on day 0 followed by three injections (3 Rj) on days 4, 8 and 12 with the three pools of transfected cells. The statistical significance of the data was determined by Student's t-tests comparing tumor growth in the mock groups with tumor growth in the CD70-or sCD70-injected groups. Values of Po.05 were considered significant and are identified by a*. Table 1) . The difference in tumor size between groups of mice injected with mock-or sCD70-transfected fibroblasts was large and statistically significant (Po.00001).
Involvement of T lymphocytes in tumor rejection induced by sCD70-secreting MC57 fibroblasts
To assess the involvement of T lymphocytes in these in vivo antitumor responses mediated by sCD70-secreting fibroblasts, the same populations of cells were injected in parallel into athymic T cell-deficient BALB/c nu/nu mice and into immunocompetent BALB/c mice. As for previous experiments, mice were first injected with a mixture of 5 Â 10 4 live wt TS/A tumor cells and 5 Â 10 4 irradiated mock or sCD70-transfected MC57 fibroblasts and then restimulated three times by the irradiated transfected fibroblasts. Whereas in BALB/c mice the injections of sCD70-transfected fibroblasts slowed the growth of the wt tumors, in nude mice the wt tumors grew with identical kinetics with or without sCD70-secreting fibroblasts (Fig  6) . These results suggested that T lymphocyte responses were involved in the antitumor response induced in immunocompetent BALB/c mice by sCD70-secreting allogenic MC57 fibroblasts.
Induction of a protective memory against wt TS/A tumor cells by injection of sCD70-secreting TS/A tumor cells
The ability of sCD70-secreting TS/A tumor cells to elicit a systemic memory immunity against wt TS/A tumor cells Figure 4 Injection of sCD70-secreting TS/A cells induces an increase of CD8 þ /CD27 þ T lymphocytes population. On day 9 after tumor injection (following the injection protocol used in Figure 2b ), splenocytes were harvested and pooled from two mice from each of the three groups. They were stained with anti-mouse PE-conjugated CD27 antibody and with either anti-mouse FITC-conjugated CD3 antibody, anti-mouse FITCconjugated CD8 antibody or with anti-mouse FITC-conjugated CD16 antibody as indicated in Materials and methods.
Antitumor immunity induced by soluble CD70 C Cormary et al was investigated in immunocompetent BALB/c mice that remained tumor-free 45 days after the primary injection. Mice that had been injected with a mixture of wt TS/A tumor cells plus sCD70-secreting TS/A cells and reinjected three times (Fig 2b) and which remained tumor-free were challenged in both flanks with 5 Â 10 4 live wt TS/A tumor cells; simultaneously naive mice were injected with the same tumor cell suspension. In the sCD70-secreting TS/A injected group, 70% of wt tumors did not develop (Fig 7b) whereas all wt tumors grew in control naive BALB/c mice. Concerning their mean tumor size (Fig 7a) , growth kinetics were statistically different (Po.001). These results indicate that sCD70-secreting TS/A tumor cells injected in the periphery of wt tumors for 12 days generated an effective and long-lasting antitumor response in immunocompetent mice. This response induces an efficient protective memory against wt TS/A tumor challenge.
Inhibition of in vitro tumor cell proliferation by in vivo activated splenocytes
To confirm the ability of sCD70-secreting TS/A tumor cells to elicit protective immunity against wt tumor cells, the capacity of in vivo and in vitro stimulated splenocytes to inhibit wt tumor cell proliferation was investigated in vitro. Three groups of mice were injected with mock, CD70-or sCD70-transfected irradiated TS/A cells. The mock group was composed of naive mice, whereas the CD70 and sCD70 groups were composed of the tumorfree mice that had been challenged 45 days before. Figure 8 shows that the splenocytes harvested from CD70-or sCD70 TS/A injected mice and restimulated in vitro were able to inhibit mock TS/A tumor cell proliferation in vitro. The results are expressed as the percentage of inhibition of mock TS/A proliferation induced by splenocytes harvested from CD70-or sCD70-injected mice compared to the proliferation of mock TS/A tumor in the presence of splenocytes from mock-injected mice. The presence of CD70 molecules during the in vivo priming seems to be essential in developing inhibition of tumor cell proliferation by splenocytes. Student's t-test analysis showed that there was a statistically significant difference (Po.0001) be- Surprisingly, in vitro restimulation by CD70 or sCD70 TS/A cells did not increase the inhibitory activity of the restimulated splenocytes. Indeed, no differences were observed between the differently in vitro restimulated splenocytes (Fig 8) . Thus, the injection of TS/A tumor cells expressing CD70 molecules either on their membrane or in the soluble form induced an activation of splenocytes. This in vivo activation is necessary to induce an inhibitory activity against wt TS/A tumor cell growth which can be detected after in vitro restimulation with CD70 or sCD70 TS/A tumor cells.
Discussion
Stable transfectants expressing membrane-bound CD70 were established and used in various experiments. The injection of these transfectants efficiently enhanced antitumor immunity in BALB/c mice. 24, 26 The efficiency of soluble secreted CD70 had never been tested. To undertake this study, sCD70 stable secreting transfectants were injected into immunocompetent mice simultaneously with wt tumor cells. The results of the present study indicate that the secretion of soluble human CD70 by autologous TS/A tumor cells or allogenic MC57 fibroblasts, in the periphery of wt MHC-I-positive tumors, induced in vivo T-cell-mediated wt tumor rejection and the initiation of a protective antitumor memory response.
Using cDNA for membrane human CD70, we constructed a viral-derived vector carrying the soluble form of human CD70 (sCD70). Through stable transfections, we obtained clones secreting sCD70 molecules that were either the MHC-I-positive (H-2 d ) mammary adenocarcinoma cell line TS/A or the allogenic (H-2 b ) MC57 fibroblast line. In immunocompetent mice, the secretion of soluble CD70 by autologous TS/A tumor cells or allogenic MC57 fibroblasts in the periphery of wt tumors was able to elicit protective immunity against wt tumor cell growth. The results obtained with sCD70-secreting TS/A and those obtained with sCD70-secreting MC57 fibroblasts were similar. This similarity could be explained by the activity of the sCD70 molecule alone. The purification of soluble CD70 molecules and the effect of sCD70 alone are currently under investigation. Moreover, the antitumor activity increased with the time of contact between sCD70-secreting cells and wt tumors. However, large differences were observed between mice from the same group. In groups of mice injected with sCD70-secreting TS/A cells or sCD70-secreting MC57 fibroblasts, some mice developed tumors that grew with similar kinetics to those of mock-injected mice, whereas other mice never developed tumors. These individual variations in mouse models could be explained, as suggested by Kourilsky's group, 27 by the moment of the first encounter between specific T cells and the antigen. The frequency of these specific T cells would therefore be different in different mice and would be responsible for the capacity to reject the tumor or not. Several kinds of effector cells could be responsible for this CD70-induced antitumor response and in particular NK cells or T lymphocytes. Indeed, Kelly et al 16 showed that CD27/CD70 interactions promote NK and T-cell-mediated tumor rejection. They discussed the role of MHC class I tumor cell status, which induces innate or adaptative immune tumor responses. MHC class I-deficient tumor cells were rejected by NK cells, whereas the antitumor activity directed against MHC class I-sufficient tumor cells involved T effector lymphocytes. Our experiments confirmed the analysis of Kelly et al since TS/A tumor cells are MHC class I-positive and the antitumor response induced by sCD70 secreting cells in this model was shown to be mainly mediated by T lymphocytes rather than by NK cells. Indeed, the differences in tumor growth in vivo in immunocompetent versus athymic nude mice suggest that mainly T lymphocytes are involved. Moreover, cytometric analysis of splenocytes harvested from sCD70-injected mice further confirmed T-lymphocyte involvement, because the percentage of T lymphocytes (CD3 þ /CD27 þ ) and especially the subpopulation of CD8 þ /CD27 þ cells were increased in these mice, whereas no difference was observed in the number of CD16 þ /CD27 þ cells. CD70-expressing tumor cells were also able to induce an effective antitumor T cell memory, which is in agreement with the results obtain by Smyth's group. 16 Moreover, our results also show that sCD70-secreting transfected cells are as efficient as membrane CD70-expressing transfectants.
Splenocytes from mice injected with sCD70-secreting tumor cells were able to inhibit tumor cells proliferation in vitro. Interestingly, this activity was aimed towards wt tumors and did not increase when the target TS/A cells expressed CD70. Furthermore, in vitro restimulation with wt, membrane or soluble CD70-expressing tumor cells had similar consequences. These results suggest that in vivo expression of CD70 molecules is necessary to induce this inhibitory activity of splenocytes and that in vitro restimulation is mainly linked to antigens expressed on all the TS/A-transfected cells, probably TAA. Similarly, Brown et al 15 suggested that CD27/CD70 interactions can selectively enhance differentiation of murine antigen allospecific CD8 þ T-cell effectors. And recently, Yamada et al 14 showed an enhancement of autologous antigenspecific CTL activity induced by CD27/CD70 interactions, which involved the perforin/granzyme B pathway.
The role of CD27/CD70 interactions in T-cell activation has interesting perspectives in cancer immunotherapy. Different protocols in human or murine models have already confirmed this using membrane expressed forms of CD70 molecules. 8, 28, 29 The results obtained in vitro concerning the inhibition of in vitro tumor proliferation were similar with the two forms of CD70-expressing cells. However, in our models, in vivo experiments showed that tumor rejection by immunocompetent mice is more efficient with CD70-secreting cells than with cells expressing membrane CD70. This difference could be explained by a better distribution of sCD70 molecules in vivo. sCD70 could penetrate into lymph nodes near the tumor site, which would induce an earlier T-cell recruitment and thus a more efficient activation of the antitumor response.
Furthermore, another advantage of sCD70 could be its simplified use. Recent research has been undertaken to develop adoptive cellular therapies as an alternative to chemotherapy and/or radiation for cancer. The secretion of sCD70 by semiallogenic fibroblast lines, which play the role of an immune adjuvant, could be a promising approach. Moreover, some protocols have already tested semiallogenic fibroblasts and other immune adjuvants. Glick et al 30 showed an increased immune response against glioma in mice treated with semiallogenic fibroblasts secreting IL-2. A therapeutic antitumor response was also induced with epitope-pulsed fibroblasts genetically transfected to express CD80 and produce IFNg. 31 The efficiency of our sCD70-secreting allogenic fibroblasts could be further increased by the presence of autologous TAA expressed on autologous MHC-I antigens if semiallogenic fibroblasts were used to secrete sCD70. Other work in different models using fibroblasts is also encouraging. Fibroblasts have been either pulsed with TAAs, or genetically transfected to express CD80 and CD86 used in a phase I clinical trial. [32] [33] [34] Thus, it would be very interesting to study the antitumor response induced in different MHC class I status tumor models treated with semiallogenic fibroblasts pulsed with autologous TAA peptides and secreting sCD70.
